BioInfra Co., Ltd. (199730.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩1,601 (-1.17%) as of
Key statistics
- Market cap
- 7.79B
- Dividend yield
- 18.52%
- 52-week range
- 0.00 – 5,420.00
- Beta
- 0.52
- Revenue (TTM)
- 25.62B
- Profit margin
- -32.34%
About BioInfra Co., Ltd.
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances. The company was founded in 2007 and is based in Yongin-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yongin-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.